Limmatech Biologics

Developing bioconjugate vaccines using glycoengineering and protein glycosylation techniques

placeSchlieren, Zurich, Switzerland calendar_todayFounded 2015 groups40 employees language lmtbio.com

Social engagement

Social engagement: 5.8K social following, 2 posts in the last 12 months — below the industry typical range.

Investor mix

6 investors on record; lead investors include Tenmile, Adjuvant Capital, AXA Investment Managers, REPAIR Impact Fund.

Investor typeCountShare
Venture capital350%
Bank & private debt117%
Other / undisclosed233%
Coming soon